Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
about
Interferon alpha for the adjuvant treatment of cutaneous melanomaInterferon alpha for the adjuvant treatment of cutaneous melanomaTrial WatchChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Long-term survival as a treatment benchmark in melanoma: latest results and clinical implicationsThe past, present and future of immunotherapy against tumorTrial Watch-Immunostimulation with cytokines in cancer therapyWhole Body Melanoma Transcriptome Response in MedakaSurgery of primary melanomas.Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up.Utility of adjuvant systemic therapy in melanoma.Melanoma in pediatric, adolescent, and young adult patients.Cutaneous melanoma: new advances in treatment.Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulationCombination immunotherapy for high-risk resected and metastatic melanoma patientsOutcome after therapeutic lymph node dissection in patients with unknown primary melanoma siteAntibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma.Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data.Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatmentImmunotherapy for metastatic solid cancersCancer immunotherapy in clinical practice -- the past, present, and future.Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia GroupNo increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C.Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Genomic Classification of Cutaneous MelanomaPrognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis.Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma.Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfaOutcomes for lymph node-positive cutaneous melanoma over two decades.Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments.TYRO3-mediated regulation of MITF: a novel target in melanoma?Systematic review of medical treatment in melanoma: current status and future prospects.Adjuvant therapy: melanomaNew Perspectives of "omics" Applications in Melanoma Research.Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.
P2860
Q24201908-385859A8-9E6C-4CB4-B685-CFFD6A7EFBDBQ24235257-A7677B43-CEF1-4FC5-98F7-422A17AD84B8Q24618653-53852684-AAEA-421A-BA1A-DF40CC6E920FQ26770492-655AE19B-D546-4EC5-89F1-75203D242880Q26775546-148AE936-A292-42B9-95B1-5918EF8A08BFQ26799896-D0FE3D8A-219E-4F74-A22E-7645D0AD7D87Q28078725-39FDCC27-E9EB-4445-BD1A-07936719291BQ28551986-FDEFAA27-C38A-458D-9BD0-10224037CF60Q30356095-6F7342C5-87FC-40DA-8734-40A9D8DBD656Q30412300-0627C1CD-54A5-4475-AAE6-0ECAD737A9E4Q31150157-D3D6EEF8-1C3E-482D-809A-7B193C3C7F8CQ33484065-77F24580-DF6D-47A8-8071-2CDFC5C6ABA9Q33554622-98CC02EC-C905-4011-9E3C-213006D449D7Q33558587-EF6BECFE-E3A7-4A59-980F-42C52676C588Q33631126-54675CCD-76FE-4508-A8ED-951DEBE82161Q33737498-C10786C8-774C-4ECE-954D-F46B37140978Q33911465-8B25D0FC-FA66-4A34-A70D-69855E272FA5Q34000700-3C8F5CAF-ED56-4052-8DE4-18BFBADE7B44Q34020065-606A5CF1-EE66-45BD-B188-1B0E3B423221Q34035015-026F70DC-D95A-4D2B-B595-0CE5AEE90C48Q34099760-2B2DEE5C-F7F8-43F2-81B6-C3956E221A81Q34114136-83DD6BB3-B392-4F9B-A072-F5398363AA70Q34219970-E287889E-330F-4BBB-95AF-2C73439BF538Q34309399-E42C9B33-69F0-4815-9C14-6A8AE9AE2323Q34484199-CCE1142F-8EE0-4C5C-BAE3-A84A7319684DQ34511200-2A45D1F9-EA5A-4628-A204-70A12466D245Q34594791-C35AC3B4-D148-4A96-A57A-9B67EB0897D4Q34640145-A29BE8DA-FA00-4329-8F28-1FB8E293C6A8Q34642874-A185AB8C-067D-4E24-831D-7B7E40DEED72Q34670776-90A847AE-37CB-4082-9337-DC7A52ABED31Q34702316-042CA5F8-CFA0-46EC-A530-62FB3EBF98E1Q34986199-FE29B808-2532-4D8D-9F59-16CD36EA6EB8Q35020518-BB55223D-B99C-4E6F-829C-9D659C91A7D3Q35028465-47CA52D7-5212-433D-BE3B-660163A28CD1Q35047686-4A7C89DB-26BE-4F1D-84F7-12B363A9256AQ35173817-855449B4-6628-4B76-94F9-7FF9FFA504DDQ35584299-9BE8CD49-6A17-4ED8-98DE-B73EF0595DCBQ35636225-3D95EDA4-B147-4F8C-9B70-A8C53D7BE4AFQ35670683-B4856B61-1CCB-482F-A111-29690B159122Q35698637-FEBC7CBF-8DF6-400D-B0D5-90C57FCCB127
P2860
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Adjuvant therapy with pegylate ...... a randomised phase III trial.
@ast
Adjuvant therapy with pegylate ...... a randomised phase III trial.
@en
Adjuvant therapy with pegylate ...... a randomised phase III trial.
@nl
type
label
Adjuvant therapy with pegylate ...... a randomised phase III trial.
@ast
Adjuvant therapy with pegylate ...... a randomised phase III trial.
@en
Adjuvant therapy with pegylate ...... a randomised phase III trial.
@nl
prefLabel
Adjuvant therapy with pegylate ...... a randomised phase III trial.
@ast
Adjuvant therapy with pegylate ...... a randomised phase III trial.
@en
Adjuvant therapy with pegylate ...... a randomised phase III trial.
@nl
P2093
P1433
P1476
Adjuvant therapy with pegylate ...... a randomised phase III trial.
@en
P2093
Alain Spatz
Alessandro Testori
Alexander M M Eggermont
Axel Hauschild
Cornelis J A Punt
EORTC Melanoma Group
Elena Musat
François Salès
Jeremy Marsden
Martin Gore
P304
P356
10.1016/S0140-6736(08)61033-8
P407
P577
2008-07-01T00:00:00Z